POSIFLEX-TECHNOLOGY
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, today announced its latest mobile POS tablet offering - the Opera MT-6200 Series, which explores mobility and efficiency with sleek, lightweight yet semi-rugged designs. It supports Android 13 with GMS Certification or Windows 11 IoT OS, available in both x86 and RISC variants. With screen sizes of 8" and 10.1", the series features dockability with a USB Type-C connector, allowing for fast power charging. Complemented by a variety of POS accessories to enhance functionality, they are designed to meet the demands of the mobile economy across various industries. This includes retail stores, hospitality, logistics, inventory/warehouse management, and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624392969/en/
The Posiflex Opera MT-6200 Series Mobile POS Tablet (Photo: Business Wire)
Superior Durability for Tough Applications
Leveraging Posiflex's cutting-edge engineering excellence, the Opera MT-6200 Series achieves a harmonious balance between the conflicting demands of tablets. It combines a lightweight and thin design with high-performance computing and semi-rugged durability. Equipped with a Corning Gorilla III touch screen, a PCAP multi-touch TFT LCD with 300nits brightness. The tablet is ideal for heavy use in various environments with ease. To ensure durability, the series incorporates semi-rugged designs, including IP54 water and dust resistance. It can withstand drops from 1 meter (1.2 meters with a protective case) and features a unique anti-slip design, providing a secure grip during handheld use. These elements collectively make the Opera MT-6200 Series resilient against the challenges of daily use.
Efficient USB Type-C for Fast Charging
Fast power charging and power efficiency are also essential to support the superior mobility of POS tablets. The Opera MT-6200 Series features an IPX7 waterproof USB Type-C connector for docking and rapid power charging. This feature enhances the overall user experience, providing convenience and efficiency for on-the-go professionals in various business environments. In particular, the smart docking station has a special bracket for protection and convenient charging, but when the tablet is in a rubber protective case, it can be docked directly to the charger without removing the case.
Flexible Functions for Customizable User Experience
In addition to a built-in 2D scanner and NFC module, Opera MT-6200 Series tablets offer programmable buttons on both sides of the screen bezel for customizable functionality, allowing customization for your specific applications. Opera MT-6200 series leads the way with seamless connectivity, supporting WiFi 5/6 and Bluetooth 5.0/5.2, ensuring a superior and efficient user experience.
Wide Range of Accessories to Extend Functionality and Maximize Convenience
As one of the manufacturers in the world capable of producing a complete range of POS terminals and peripherals from a single source, Posiflex offers a wide range of optional accessories including fingerprint reader, MSR, shoulder strap, protective case with rotatable handheld strap, touch pen and more. The smart docking station is also equipped with a variety of I/O ports to extend the functions for stationary operations - all to maximize flexibility, user value and convenience.
About POSIFLEX Group
Posiflex Group is a global leading Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Software-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624392969/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom